Livanova plc has won FDA approval to expand its Vagus nerve stimulation (VNS) therapy to treat patients suffering from epilepsy as young as four years of age with partial onset seizures that are refractory to medications. Previously, the London-based company had approval for its Aspire device to patients ages 12 and older.